Novavax Share Price Skyrockets on $1.2 Billion Deal with Sanofi for Covid-Flu Shot – Biggest Increase on Record!
Shares of Novavax Inc. skyrocketed after the company announced a substantial $1.2 billion licensing agreement with Sanofi, aimed at commercializing a combined Covid-19 and flu vaccine. This agreement includes significant upfront payments of $500 million, with an additional $700 million contingent upon meeting various development, regulatory, and launch milestones. Novavax will also receive tiered royalties from vaccine sales under the terms of the agreement, alongside a 5% minority equity stake in the US company granted …